Literature DB >> 10903297

Digestive system disorders: gastroesophageal reflux disease.

D A Katzka1.   

Abstract

This article comes from Clinical Evidence (1999; 1 : 145-153), a new resource for clinicians produced jointly by the BMJ Publishing Group and the American College of Physicians-American Society of Internal Medicine. Clinical Evidence is an extensively peer-reviewed publication that summarizes the best available evidence on the effects of common clinical interventions gleaned from thorough searches and appraisal of the world literature. It became available in the United States late last year. Please see advertisement for more information or, alternatively, visit the web site at www. evidence.org.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903297      PMCID: PMC1070977          DOI: 10.1136/ewjm.173.1.48

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  37 in total

1.  Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

2.  Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease.

Authors:  D A Revicki; S Sorensen; P N Maton; R C Orlando
Journal:  Dig Dis       Date:  1998 Sep-Oct       Impact factor: 2.404

3.  Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation.

Authors:  A Csendes; I Braghetto; P Burdiles; G Puente; O Korn; J C Díaz; F Maluenda
Journal:  Surgery       Date:  1998-06       Impact factor: 3.982

4.  Squamous islands in Barrett's esophagus: what lies underneath?

Authors:  P Sharma; T G Morales; A Bhattacharyya; H S Garewal; R E Sampliner
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

5.  Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.

Authors:  L P Leite; B T Johnston; R J Just; D O Castell
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

6.  Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.

Authors:  I Wiklund; K D Bardhan; S Müller-Lissner; M A Bigard; G Bianchi Porro; J Ponce; J Hosie; M Scott; D Weir; C Fulton; K Gillon; R Peacock
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-02

7.  Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.

Authors:  C M Bate; J R Green; A T Axon; G Tildesley; F E Murrays; S M Owen; C Emmas; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1998-01       Impact factor: 8.171

8.  Effect of antireflux operation on Barrett's mucosa.

Authors:  W A Williamson; F H Ellis; S P Gibb; D M Shahian; H T Aretz
Journal:  Ann Thorac Surg       Date:  1990-04       Impact factor: 4.330

9.  Effects of ranitidine treatment on patients with asthma and a history of gastro-oesophageal reflux: a double blind crossover study.

Authors:  T Ekström; B R Lindgren; L Tibbling
Journal:  Thorax       Date:  1989-01       Impact factor: 9.139

10.  Lack of impact of therapy on extent of Barrett's esophagus in 67 patients.

Authors:  R E Sampliner; H S Garewal; M B Fennerty; M Aickin
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.